Transverse Cerebellar DiameterNCT07675902
Transverse Cerebellar Diameter and Abdominal Circumference Ratio Versus Mid-Thigh Circumference and Femur Length Ratio in Assessment of Gestational Age in Normal and Growth Restricted Fetuses
An observational study of Transverse Cerebellar Diameter and Abdominal Circumference Ratio, run by Tanta University at 1 site in Egypt.
Trial summary
The aim of this research was to examine the accuracy of transcerebellar diameter to abdominal circumference ratio (TCD/AC) and mid-thigh circumference and femur length (MTC/FL) in estimating the gestational age of healthy and abnormally growing fetuses. Read more about this study
- Who is it for?
- Ages 18 to 35 years, women only
- Conditions the study is for
- Transverse Cerebellar Diameter, Abdominal Circumference Ratio, Mid-Thigh Circumference and Femur Length Ratio
- What is being tested?
- Fetal Ultrasound Assessment
- Type of treatment
- Medical device
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Oct 2023to 1 Oct 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- No healthy volunteers
- Adult
Study population: This prospective study was conducted on 100 pregnant cases at the department of Obstetrics of Tanta University Hospital.
Who may be able to join
- Pregnant women aged 18 to 35 years old.
- 24-28 weeks of gestation
- Primigravida
- Single viable fetus
- Reliable Last Menstrual Period (LMP) or first trimester ultrasonography to confirm gestational age.
Who cannot join
- Chromosomal abnormalities.
- Any medical disease that affect fetal growth.
Trial locations and contacts
1 site in 1 country.
About this study
The aim of this research was to examine the accuracy of transcerebellar diameter to abdominal circumference ratio (TCD/AC) and mid-thigh circumference and femur length (MTC/FL) in estimating the gestational age of healthy and abnormally growing fetuses.
Read the detailed description
Fetal growth restriction (FGR) is poor fetal growth, typically defined by weight under the 10th percentile, due to maternal, placental, and fetal factors.
The transcerebellar diameter to abdominal circumference ratio (TCD/AC) in ultrasound aids in predicting FGR, mainly through abdominal circumference (AC), while transverse cerebellar diameter (TCD) is less often related to fetal growth issues.
- Conditions
- Transverse Cerebellar Diameter, Abdominal Circumference Ratio, Mid-Thigh Circumference and Femur Length Ratio, Gestational Age, Growth Restricted Fetuses
- Being tested
- Fetal Ultrasound Assessment
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fetal Ultrasound AssessmentDevice
All enrolled pregnant women underwent a standardized obstetric ultrasound examination between 24 and 28 weeks of gestation.
| Study group | Role | What they receive |
|---|---|---|
| Group A | Pregnant women with normal fetal growth. Receives: Device: Fetal Ultrasound Assessment | |
| Group B | Pregnant women suffering from intrauterine growth restriction (IUGR). Receives: Device: Fetal Ultrasound Assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Diagnostic accuracy of transcerebellar diameter to abdominal circumference ratio (TCD/AC) ratio
Assessment of the diagnostic performance of the transcerebellar diameter to abdominal circumference ratio (TCD/AC) in predicting intrauterine growth restriction (IUGR)
Measured: At the time of ultrasound examination (24-28 weeks of gestation)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2026
- Study start1 Oct 2023
- Primary completion1 Oct 2024
- Study completion1 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Transverse Cerebellar DiameterStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nora Abdallah Hassan Abdallah, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07675902
- Sponsor's protocol ID
- 36264MS311/9/23
- Status last verified
- Jun 2026
- First submitted
- 23 Jun 2026
- Last updated
- 30 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Transverse Cerebellar Diameter and Abdominal Circumference Ratio Versus Mid-Thigh Circumference and Femur Length Ratio in Assessment of Gestational Age in Normal and Growth Restricted Fetuses
- ClinicalTrials.gov ID
- NCT07675902
- Acronym / sponsor ID
- 36264MS311/9/23
- Conditions
- Transverse Cerebellar Diameter, Abdominal Circumference Ratio, Mid-Thigh Circumference and Femur Length Ratio, Gestational Age, Growth Restricted Fetuses
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 1 Oct 2023 (actual)
- Primary completion
- 1 Oct 2024 (actual)
- Study completion
- 1 Oct 2024 (actual)
- First posted
- 30 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this research was to examine the accuracy of transcerebellar diameter to abdominal circumference ratio (TCD/AC) and mid-thigh circumference and femur length (MTC/FL) in estimating the gestational age of healthy and abnormally growing fetuses.
Detailed description
Fetal growth restriction (FGR) is poor fetal growth, typically defined by weight under the 10th percentile, due to maternal, placental, and fetal factors.
The transcerebellar diameter to abdominal circumference ratio (TCD/AC) in ultrasound aids in predicting FGR, mainly through abdominal circumference (AC), while transverse cerebellar diameter (TCD) is less often related to fetal growth issues.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A | – | Device: Fetal Ultrasound AssessmentPregnant women with normal fetal growth. |
| Group B | – | Device: Fetal Ultrasound AssessmentPregnant women suffering from intrauterine growth restriction (IUGR). |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- This prospective study was conducted on 100 pregnant cases at the department of Obstetrics of Tanta University Hospital.
Key inclusion criteria (5 listed)
- Pregnant women aged 18 to 35 years old.
- 24-28 weeks of gestation
- Primigravida
- Single viable fetus
- Reliable Last Menstrual Period (LMP) or first trimester ultrasonography to confirm gestational age.
Key exclusion criteria (2 listed)
- Chromosomal abnormalities.
- Any medical disease that affect fetal growth.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fetal Ultrasound AssessmentAll enrolled pregnant women underwent a standardized obstetric ultrasound examination between 24 and 28 weeks of gestation. | Device | Group A, Group B |
Primary outcome
Diagnostic accuracy of transcerebellar diameter to abdominal circumference ratio (TCD/AC) ratio
Time frame: At the time of ultrasound examination (24-28 weeks of gestation)
Assessment of the diagnostic performance of the transcerebellar diameter to abdominal circumference ratio (TCD/AC) in predicting intrauterine growth restriction (IUGR)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Transverse Cerebellar Diameter and Abdominal Circumference Ratio, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Diagnostic accuracy of transcerebellar diameter to abdominal circumference ratio (TCD/AC) ratio (time frame: At the time of ultrasound examination (24-28 weeks of gestation)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026.